Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells

Mary J.C. Hendrix; Irawati Kandela; Andrew P. Mazar; Elisabeth A. Seftor; Richard E.B. Seftor; Naira V. Margaryan; Luigi Strizzi; Gëorge F. Murphy; Georgina V. Long; Richard A Scolyer

doi:10.1038/labinvest.2016.107

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2006

Tracking germinal center B cells expressing germ-line immunoglobulin γ1 transcripts by conditional gene targeting

Stefano Casola, Giorgio Cattoretti, Nathalie Uyttersprot, Sergei B. Koralov, Jane Seagal, Zhenyue Hao, Ari Waisman, Angela Egert, Dvora Ghitza, Klaus Rajewsky

Article2015

Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma

Katharine M. Hardy, Luigi Strizzi, Naira V. Margaryan, Kanika Gupta, Gëorge F. Murphy, Richard A Scolyer, Mary J.C. Hendrix

Preprint2023

Data from Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma

Katharine M. Hardy, Luigi Strizzi, Naira V. Margaryan, Kanika Gupta, Gëorge F. Murphy, Richard A Scolyer, Mary J.C. Hendrix

Preprint2023

Data from Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma

Katharine M. Hardy, Luigi Strizzi, Naira V. Margaryan, Kanika Gupta, Gëorge F. Murphy, Richard A Scolyer, Mary J.C. Hendrix

Preprint2023

Supplementary Methods from Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma

Katharine M. Hardy, Luigi Strizzi, Naira V. Margaryan, Kanika Gupta, Gëorge F. Murphy, Richard A Scolyer, Mary J.C. Hendrix